Intranasal Polymeric and Lipid-Based Nanocarriers for CNS Drug Delivery

Pharmaceutics, Journal Year: 2023, Volume and Issue: 15(3), P. 746 - 746

Published: Feb. 23, 2023

Nanomedicine is currently focused on the design and development of nanocarriers that enhance drug delivery to brain address unmet clinical needs for treating neuropsychiatric disorders neurological diseases. Polymer lipid-based carriers are advantageous central nervous system (CNS) due their safety profiles, drug-loading capacity, controlled-release properties. nanoparticles (NPs) reported penetrate blood–brain barrier (BBB) have been extensively assessed in vitro animal models glioblastoma, epilepsy, neurodegenerative disease. Since approval by Food Drug Administration (FDA) intranasal esketamine treatment major depressive disorder, administration has emerged as an attractive route bypass BBB CNS. NPs can be specifically designed tailoring size coating with mucoadhesive agents or other moieties promote transport across nasal mucosa. In this review, unique characteristics polymeric desirable explored addition potential repurposing CNS disorders. Progress using nanostructures treatments various diseases also described.

Language: Английский

---

Levodopa-loaded nanoparticles for the treatment of Parkinson's disease

Journal of Controlled Release, Journal Year: 2023, Volume and Issue: 360, P. 212 - 224

Published: June 25, 2023

Parkinson's disease (PD) is a neurodegenerative disorder characterized by degeneration of dopaminergic neurons in the substantia nigra pars compacta (SNpc) resulting dopamine (DA) deficiency, which manifests itself motor symptoms including tremors, rigidity and bradykinesia. Current PD treatments aim at symptom reduction through oral delivery levodopa (L-DOPA), precursor DA. However, L-DOPA to brain inefficient increased dosages are required as progresses, serious side effects like dyskinesias. To improve treatment efficacy reduce effects, recent research focuses on encapsulation into polymeric- lipid-based nanoparticles (NPs). These formulations can protect from systemic decarboxylation DA central nervous system. Additionally, NPs be modified with proteins, peptides antibodies specifically targeting blood-brain barrier (BBB), thereby reducing free Alternative approaches for NP-encapsulated include intravenous (IV) administration, transdermal using adhesive patches direct intranasal facilitating therapeutic concentrations brain. This review provides an overview advances NP-mediated brain, debates challenges future perspectives field.

Language: Английский

---

Synthesis of a Rivastigmine and Insulin Combinational Mucoadhesive Nanoparticle for Intranasal Delivery

Polymers, Journal Year: 2024, Volume and Issue: 16(4), P. 510 - 510

Published: Feb. 13, 2024

Efficient drug delivery remains a critical challenge for treating neurodegenerative diseases, such as Alzheimer’s disease (AD). Using innovative nanomaterials, delivering current medications like acetylcholinesterase inhibitors to the brain through intranasal route is promising strategy managing AD. Here, we developed unique combinational system based on N,N,N-trimethyl chitosan nanoparticles (NPs). These NPs encapsulate rivastigmine, most potent inhibitor, along with insulin, complementary therapeutic agent. The spherical exhibited zeta potential of 17.6 mV, size 187.00 nm, and polydispersity index (PDI) 0.29. Our findings demonstrate significantly improved transport efficiency sheep nasal mucosa using compared solutions. efficiencies 73.3% rivastigmine 96.9% surpassing solutions, which showed 52% 21% insulin ex vivo. results highlight new approach enhancing efficiency. mucoadhesive offer novel simultaneous cerebral could prove helpful in developing effective treatments AD other conditions.

Language: Английский

---

Nanocarriers-mediated nose-to-brain drug delivery: A novel approach for the management of Alzheimer’s disease

Journal of Drug Delivery Science and Technology, Journal Year: 2024, Volume and Issue: 98, P. 105855 - 105855

Published: June 8, 2024

Language: Английский

---

Tadpole-Like Anisotropic Polymer/Lipid Janus Nanoparticles for Nose-to-Brain Drug Delivery: Importance of Geometry, Elasticity on Mucus-Penetration Ability

Molecular Pharmaceutics, Journal Year: 2024, Volume and Issue: 21(2), P. 633 - 650

Published: Jan. 2, 2024

Asymmetric geometry (aspect ratio >1), moderate stiffness (i.e., semielasticity), large surface area, and low mucoadhesion of nanoparticles are the main features to reach brain by penetrating across nasal mucosa. Herein, a new application has been presented for use multifunctional Janus (JNPs) with controllable size as nose-to-brain (N2B) delivery system changing proportions Precirol ATO 5 polycaprolactone compartments other operating conditions. To bring light N2B JNPs, results in comparison polymer solid lipid nanoparticles, which frequently used literature regarding their biopharmaceutical aspects: permeability through The morphology JPs were observed via cryogenic-temperature transmission electron microscopy images, particle sizes verified dynamic scattering, atomic force microscopy, scanning microscopy. Although all NPs showed penetration mucus barrier, best increase was asymmetric semielastic have interaction ability layer. This study presents promising field suitable delivery, potentially benefiting treatment tumors central nervous diseases.

Language: Английский

---

Research progress on intranasal treatment for Parkinson's disease

Neuroprotection/Neuroprotection (Chichester, England. Print), Journal Year: 2024, Volume and Issue: 2(2), P. 79 - 99

Published: April 21, 2024

Abstract Parkinson's disease (PD) is the second most prevalent neurodegenerative disorder globally, significantly affecting quality of life affected individuals. Systemic drug delivery to brain inefficient because first‐pass metabolism, blood‐brain barrier (BBB), and blood‐cerebrospinal fluid barrier. This inefficiency necessitates increased dosage as progresses, leading severe side effects that compromise efficacy medication. Nose‐to‐brain (N2B) administration bypasses BBB, allowing both small molecules large protein substances central nervous system. Compared with systemic administration, this method enhances bioavailability, reduces enzymatic degradation, minimizes adverse reactions. However, N2B system associated several critical challenges, including mucociliary clearance, translocation via efflux mechanisms. paper provides a comprehensive overview current research progress in intranasal treatment PD, considering preclinical clinical studies, discusses physiological aspects limitations its

Language: Английский

---

Anticancer Applications of Essential Oils Formulated into Lipid-Based Delivery Nanosystems

Pharmaceutics, Journal Year: 2022, Volume and Issue: 14(12), P. 2681 - 2681

Published: Dec. 1, 2022

The use of natural compounds is becoming increasingly popular among patients, and there a renewed interest scientists in nature-based bioactive agents. Traditionally, herbal drugs can be taken directly the form teas/decoctions/infusions or as standardized extracts. However, disadvantages compounds, especially essential oils, are their instability, limited bioavailability, volatility, often irritant/allergenic potential. these active substances stabilized by encapsulation administered nanoparticles. This brief overview summarizes latest results application nanoemulsions, liposomes, solid lipid nanoparticles, nanostructured carriers used drug delivery systems oils for individual secondary metabolites applicable cancer therapy. Although discussed agents not typical anticancer agents, after inclusion into aforesaid formulations improving stability bioavailability and/or therapeutic profile, they indicated anti-tumor activity became interesting with treatment In addition, co-encapsulation synthetic nanoformulations aim to achieve synergistic effect chemotherapy discussed.

Language: Английский

---

Drug Delivery Systems as a Strategy to Improve the Efficacy of FDA-Approved Alzheimer’s Drugs

Pharmaceutics, Journal Year: 2022, Volume and Issue: 14(11), P. 2296 - 2296

Published: Oct. 26, 2022

Alzheimer’s disease (AD) is the most common form of dementia, with a high impact worldwide, accounting for more than 46 million cases. The continuous increase AD demands fast development preventive and curative therapeutic strategies that are truly effective. drugs approved treatment classified into acetylcholinesterase inhibitors N-methyl-D-aspartate receptor antagonists. effectiveness those hindered by their restricted access to brain due blood–brain barrier, low bioavailability, poor pharmacokinetic properties. In addition, reported have undesirable side effects. Several drug delivery systems (DDSs) been widely exploited address these issues. DDSs serve as carriers, combining ability deliver locally in targeted manner release them controlled sustained manner. As result, pharmacological raised, while unwanted effects induced unspecific distribution decrease. This article reviews recently developed efficacy Food Drug Administration-approved drugs.

Language: Английский

---

Revolutionizing Parkinson’s treatment: Harnessing the potential of intranasal nanoemulsions for targeted therapy

Drug Delivery and Translational Research, Journal Year: 2025, Volume and Issue: unknown

Published: Jan. 8, 2025

Language: Английский

---

Lyophilized Nasal Inserts of Atomoxetine HCl Solid Lipid Nanoparticles for Brain Targeting as a Treatment of Attention-Deficit/Hyperactivity Disorder (ADHD): A Pharmacokinetics Study on Rats

Pharmaceuticals, Journal Year: 2023, Volume and Issue: 16(2), P. 326 - 326

Published: Feb. 20, 2023

The study aims to investigate the ability of lyophilized nasal inserts nanosized atomoxetine HCl solid lipid nanoparticles (ATM-SLNs) transport (ATM) directly brain and overcome first-pass metabolism. In this case, 16 formulae were prepared using hot melt emulsification, stirring ultrasonication method technique. A full factorial design was established with 24 trials by optimization four variables; type (Compritol 888 ATO or stearic acid) (X1), drug ratio [(1:2) (2:1)] (X2), span 60: Pluronic f127 [(1:3) (3:1)] (X3) probe sonication time (five ten minutes) (X4). SLNs characterized for entrapment efficiency (EE%), in-vitro release after 30 min (Q30min), particle size (PS), zeta potential (ZP) polydispersity index (PDI). Design Expert® software used select optimum two formulae. morphological examination carried out a transmission electron microscope (TEM). Furthermore, eight 23 three variables: formula polymer (NOVEON AA1 HPMC K100m) (X2) concentration (X3). They evaluated inserts' physicochemical properties. selected software. insets highest desirability values (S4 S8). subjected DSC thermal stability in-vivo on rats. compared oral solution, (3 mg/kg, intraperitoneal injection) pure solution loaded in insert. showed EE% range (41.14 mg ± 1.8% 90.6 2.8%), (Q30min%) (27.11 5.9% 91.08 0.15%), ZP (-8.52 0.75 -28.4 0.212% mV), PS (320.9 110.81% nm 936.7 229.6% nm) PDI (0.222 0.132% 0.658 0.03%). Additionally, chosen, i.e., F7 F9 spherical morphology. Nasal had assay content (82.5 2.5% 103.94 3.94%), Q15min% (89.9 6.4% 100%) Muco-adhesion strength (3510.5 140.21 9319.5 39.425). results S4 S8 compatibility other excipients. also higher trans-nasal permeation targeting (211.3% 177.42%, respectively) percentages (52.7% 43.64%, respectively). To conclude, enhanced efficiency.

Language: Английский

---